Adapting Glucagon-Like Peptide-1 Receptor Agonists for Innovative Psoriasis Therapy.
2026Journal of cutaneous medicine and surgery
Tanquilut E, Dumke M, Parga A, Suhling M, Hunt J +3 more
Plain English
This study explored the potential of using glucagon-like peptide-1 (GLP-1) receptor agonists, which are typically used to treat type 2 diabetes, as a new therapy for psoriasis, a long-lasting skin condition. The review found some early evidence suggesting that GLP-1 receptor agonists may help manage psoriasis symptoms, but noted limitations like small study sizes and a lack of rigorous trials. Understanding how these medications might aid in treatment could provide new options for psoriasis patients who struggle with current therapies.
Who this helps: Patients with psoriasis looking for new treatment options.